Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: New data from the Patch in Practice trial and pooled analyses

Drug and Alcohol Dependence

Volumn 98, Issue 1-2, 2008, Pages 77-85

  David, Sean P ^a   Johnstone, Elaine C ^b   Murphy, Michael F G ^b   Aveyard, Paul ^c   Guo, Boliang ^c   Lerman, Caryn ^d   Munafò, Marcus R ^e  

^a BROWN UNIVERSITY   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

5 HT1A receptor; Nicotine replacement therapy; Pharmacogenetics; Serotonin transporter; Smoking cessation; Tryptophan hydroxylase

Indexed keywords

SEROTONIN 1A RECEPTOR; SEROTONIN TRANSPORTER; TRYPTOPHAN HYDROXYLASE;

ADULT; ARTICLE; DNA POLYMORPHISM; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADMINISTRATION, CUTANEOUS; ADULT; ALLELES; FEMALE; FOLLOW-UP STUDIES; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; NICOTINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER; TREATMENT OUTCOME; TRYPTOPHAN HYDROXYLASE;

EID: 50249169818     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.04.013     Document Type: Article

References (79)

1. Abumaria N., Ribic A., Anacker C., Fuchs E., and Flugge G. Stress upregulates TPH1 but not TPH2 mRNA in the rat dorsal raphe nucleus: identification of two TPH2 mRNA splice variants. Cell. Mol. Neurobiol. 28 3 (2008) 331-342
2. Aveyard P., Brown K., Saunders C., Alexander A., Johnstone E., Munafo M.R., and Murphy M. Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. Thorax 62 (2007) 898-903
3. Balfour D.J. Neuroplasticity within the mesoaccumbens dopamine system and its role in tobacco dependence. Curr. Drug Targets CNS Neurol. Disord. 1 (2002) 413-421
4. Balfour D.J., Benwell M.E., Graham C.A., and Vale A.L. Behavioural and adrenocortical responses to nicotine measured in rats with selective lesions of the 5-hydroxytryptaminergic fibres innervating the hippocampus. Br. J. Pharmacol. 89 (1986) 341-347
5. Balfour D.J., Graham C.A., and Vale A.L. Studies on the possible role of brain 5-HT systems and adrenocortical activity in behavioural responses to nicotine and diazepam in an elevated X-maze. Psychopharmacology (Berl) 90 (1986) 528-532
6. Bengel D., Greenberg B.D., Cora-Locatelli G., Altemus M., Heils A., Li Q., and Murphy D.L. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder. Mol. Psychiatry 4 (1999) 463-466
7. Benwell M.E., and Balfour D.J. Effects of nicotine administration and its withdrawal on plasma corticosterone and brain 5-hydroxyindoles. Psychopharmacology (Berl) 63 (1979) 7-11
8. Benwell M.E., Balfour D.J., and Anderson J.M. Smoking-associated changes in the serotonergic systems of discrete regions of human brain. Psychopharmacology (Berl) 102 (1990) 68-72
9. Cheeta S., Irvine E.E., Kenny P.J., and File S.E. The dorsal raphe nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses. Psychopharmacology (Berl) 155 (2001) 78-85
10. Cheeta S., Kenny P.J., and File S.E. The role of 5-HT1A receptors in mediating the anxiogenic effects of nicotine following lateral septal administration. Eur. J. Neurosci. 12 (2000) 3797-3802
11. Chung I.W., Kim H., Sribney W., Hong J.B., Lee C.H., Lee K.Y., Nan H.M., Kim Y.S., and Manowitz P. Tryptophan hydroxylase polymorphism is associated with age of onset of alcoholism related behaviors. Alcohol 36 (2005) 1-3
12. Cook J.W., Spring B., McChargue D.E., Borrelli B., Hitsman B., Niaura R., Keuthen N.J., and Kristeller J. Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial. Psychopharmacology (Berl) 173 (2004) 153-159
13. Curran S., Purcell S., Craig I., Asherson P., and Sham P. The serotonin transporter gene as a QTL for ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134 (2005) 42-47
14. David S.P., Brown R.A., Papandonatos G.D., Kahler C.W., Lloyd-Richardson E.E., Munafo M.R., Shields P.G., Lerman C., Strong D., McCaffery J., and Niaura R. Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation. Nicotine Tob. Res. 9 (2007) 821-833
15. David S.P., Munafò M.R., Murphy M.F., Walton R.T., and Johnstone E.C. The serotonin transporter 5-HTTLPR polymorphism and treatment response to nicotine patch: follow-up of a randomized controlled trial. Nicotine Tob. Res. 9 (2007) 225-231
16. David S.P., Murthy N.V., Rabiner E.A., Munafo M.R., Johnstone E.C., Jacob R., Walton R.T., and Grasby P.M. A functional genetic variation of the serotonin (5-HT) transporter affects 5-HT1A receptor binding in humans. J. Neurosci. 25 (2005) 2586-2590
17. David S.P., Strong D.R., Munafo M.R., Brown R.A., Lloyd-Richardson E.E., Wileyto P.E., Evins E.A., Shields P.G., Lerman C., and Niaura R. Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob. Res. 9 (2007) 1251-1257
18. Du L., Faludi G., Palkovits M., Demeter E., Bakish D., Lapierre Y.D., Sotonyi P., and Hrdina P.D. Frequency of long allele in serotonin transporter gene is increased in depressed suicide victims. Biol. Psychiatry 46 (1999) 196-201
19. Engberg G., Erhardt S., Sharp T., and Hajos M. Nicotine inhibits firing activity of dorsal raphe 5-HT neurones in vivo. Naunyn Schmiedebergs Arch. Pharmacol. 362 (2000) 41-45
20. Engel J.A., Fahlke C., Hard E., Johannessen K., Svensson L., and Soderpalm B. Serotonergic and dopaminergic involvement in ethanol intake. Clin. Neuropharmacol. 15 Suppl. 1 Pt A (1992) 64A-65A
21. Heatherton T.F., Kozlowski L.T., Frecker R.C., and Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 86 (1991) 1119-1127
22. Heils A., Mossner R., and Lesch K.P. The human serotonin transporter gene polymorphism-basic research and clinical implications. J. Neural. Transm. 104 (1997) 1005-1014
23. Heils A., Teufel A., Petri S., Stober G., Riederer P., Bengel D., and Lesch K.P. Allelic variation of human serotonin transporter gene expression. J. Neurochem. 66 (1996) 2621-2624
24. Higgins G.A., Wang Y., Corrigall W.A., and Sellers E.M. Influence of 5-HT3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. Psychopharmacology (Berl) 114 (1994) 611-619
25. Hitsman B., Spring B., Pingitore R., Munafò M.R., and Hedeker D. Effect of tryptophan depletion on the attentional salience of smoking cues. Psychopharmacology (Berl) 192 (2007) 317-324
26. Hitsman B., Spring B., Wolf W., Pingitore R., Crayton J.W., and Hedeker D. Effects of acute tryptophan depletion on negative symptoms and smoking topography in nicotine-dependent schizophrenics and nonpsychiatric controls. Neuropsychopharmacology 30 (2005) 640-648
27. Huang Y.Y., Battistuzzi C., Oquendo M.A., Harkavy-Friedman J., Greenhill L., Zalsman G., Brodsky B., Arango V., Brent D.A., and Mann J.J. Human 5-HT1A receptor C(-1019)G polymorphism and psychopathology. Int. J. Neuropsychopharmacol. 7 (2004) 441-451
28. Hughes J.R., Keely J.P., Niaura R.S., Ossip-Klein D.J., Richmond R.L., and Swan G.E. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob. Res. 5 (2003) 13-25
29. Hughes, J.R., Stead, L.F., Lancaster, T., 2000. Anxiolytics for smoking cessation. Cochrane database of systematic reviews (Online), CD002849.
30. Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. Imperial Cancer Research Fund General Practice Research Group. BMJ 306 (1993) 1304-1308
31. Imperial Cancer Research Fund General Practice Research Group. Randomised trial of nicotine patches in general practice: results at 1 year. Imperial Cancer Research Fund General Practice Research Group. BMJ 308 (1994) 1476-1477
32. Irvine E.E., Cheeta S., and File S.E. Development of tolerance to nicotine's anxiogenic effect in the social interaction test. Brain Res. 894 (2001) 95-100
33. Johnstone E.C., Yudkin P.L., Hey K., Roberts S.J., Welch S.J., Murphy M.F., Griffiths S.E., and Walton R.T. Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 14 (2004) 83-90
34. Killen J.D., Fortmann S.P., Schatzberg A.F., Hayward C., Sussman L., Rothman M., Strausberg L., and Varady A. Nicotine patch and paroxetine for smoking cessation. J. Consult. Clin. Psychol. 68 (2000) 883-889
35. Lasky-Su J.A., Faraone S.V., Glatt S.J., and Tsuang M.T. Meta-analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133 (2005) 110-115
36. LeMarquand D., Pihl R.O., and Benkelfat C. Serotonin and alcohol intake, abuse, and dependence: findings of animal studies. Biol. Psychiatry 36 (1994) 395-421
37. Lemonde S., Turecki G., Bakish D., Du L., Hrdina P.D., Bown C.D., Sequeira A., Kushwaha N., Morris S.J., Basak A., Ou X.M., and Albert P.R. Impaired repression at a 5-hydroxytryptamine 1A receptor gene polymorphism associated with major depression and suicide. J. Neurosci. 23 (2003) 8788-8799
38. Lerman C., Audrain J., Orleans C.T., Boyd R., Gold K., Main D., and Caporaso N. Investigation of mechanisms linking depressed mood to nicotine dependence. Addict. Behav. 21 (1996) 9-19
39. Lerman C., Caporaso N.E., Audrain J., Main D., Boyd N.R., and Shields P.G. Interacting effects of the serotonin transporter gene and neuroticism in smoking practices and nicotine dependence. Mol. Psychiatry 5 (2000) 189-192
40. Lerman C., Caporaso N.E., Bush A., Zheng Y.L., Audrain J., Main D., and Shields P.G. Tryptophan hydroxylase gene variant and smoking behavior. Am. J. Med. Genet. 105 (2001) 518-520
41. Lerman C., Jepson C., Wileyto E.P., Epstein L.H., Rukstalis M., Patterson F., Kaufmann V., Restine S., Hawk L., Niaura R., and Berrettini W. Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials. Neuropsychopharmacology 31 (2006) 231-242
42. Lerman C., Shields P.G., Wileyto E.P., Audrain J., Hawk Jr. L.H., Pinto A., Kucharski S., Krishnan S., Niaura R., and Epstein L.H. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychol. 22 (2003) 541-548
43. Lerman C., Tyndale R., Patterson F., Wileyto E.P., Shields P.G., Pinto A., and Benowitz N. Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin. Pharmacol. Ther. 79 (2006) 600-608
44. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., and Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274 (1996) 1527-1531
45. Li M.D., Cheng R., Ma J.Z., and Swan G.E. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 98 (2003) 23-31
46. Little K.Y., McLaughlin D.P., Zhang L., Livermore C.S., Dalack G.W., McFinton P.R., DelProposto Z.S., Hill E., Cassin B.J., Watson S.J., and Cook E.H. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am. J. Psychiatry 155 (1998) 207-213
47. Malaiyandi V., Lerman C., Benowitz N.L., Jepson C., Patterson F., and Tyndale R.F. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol. Psychiatry 11 (2006) 400-409
48. Mihailescu S., Guzman-Marin R., and Drucker-Colin R. Nicotine stimulation of dorsal raphe neurons: effects on laterodorsal and pedunculopontine neurons. Eur. Neuropsychopharmacol. 11 (2001) 359-366
49. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16 (1988) 1215
50. Munafò M., Clark T., Johnstone E., Murphy M., and Walton R. The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob. Res. 6 (2004) 583-597
51. Munafò M.R., Clark T.G., Moore L.R., Payne E., Walton R., and Flint J. Genetic polymorphisms and personality in healthy adults: a systematic review and meta-analysis. Mol. Psychiatry 8 (2003) 471-484
52. Munafò M.R., Johnstone E.C., and Mackintosh B. Association of serotonin transporter genotype with selective processing of smoking-related stimuli in current smokers and ex-smokers. Nicotine Tob. Res. 7 (2005) 773-778
53. Munafò M.R., Johnstone E.C., Wileyto E.P., Shields P.G., Elliot K.M., and Lerman C. Lack of association of 5-HTTLPR genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 398-400
54. Munafò M.R., Lingford-Hughes A.R., Johnstone E.C., and Walton R.T. Association between the serotonin transporter gene and alcohol consumption in social drinkers. Am. J. Med. Genet. B Neuropsychiatr. Genet. 135 (2005) 10-14
55. Murphy D.L., Lerner A., Rudnick G., and Lesch K.P. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. Mol. Interv. 4 (2004) 109-123
56. Niaura R., Spring B., Borrelli B., Hedeker D., Goldstein M.G., Keuthen N., DePue J., Kristeller J., Ockene J., Prochazka A., Chiles J.A., and Abrams D.B. Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment. J. Consult. Clin. Psychol. 70 (2002) 887-896
57. Nielsen D.A., Goldman D., Virkkunen M., Tokola R., Rawlings R., and Linnoila M. Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism. Arch. Gen. Psychiatry 51 (1994) 34-38
58. Nielsen D.A., Virkkunen M., Lappalainen J., Eggert M., Brown G.L., Long J.C., Goldman D., and Linnoila M. A tryptophan hydroxylase gene marker for suicidality and alcoholism. Arch. Gen. Psychiatry 55 (1998) 593-602
59. Olausson P., Akesson P., Engel J.A., and Soderpalm B. Effects of 5-HT1A and 5-HT2 receptor agonists on the behavioral and neurochemical consequences of repeated nicotine treatment. Eur. J. Pharmacol. 420 (2001) 45-54
60. Olausson P., Akesson P., Petersson A., Engel J.A., and Soderpalm B. Behavioral and neurochemical consequences of repeated nicotine treatment in the serotonin-depleted rat. Psychopharmacology (Berl) 155 (2001) 348-361
61. Olausson P., Engel J.A., and Soderpalm B. Behavioral sensitization to nicotine is associated with behavioral disinhibition; counteraction by citalopram. Psychopharmacology (Berl) 142 (1999) 111-119
62. Olausson P., Engel J.A., and Soderpalm B. Involvement of serotonin in nicotine dependence: processes relevant to positive and negative regulation of drug intake. Pharmacol. Biochem. Behav. 71 (2002) 757-771
63. Opitz K., and Weischer M.L. Volitional oral intake of nicotine in tupaias: drug-induced alterations. Drug Alcohol Depend. 21 (1988) 99-104
64. Porrino L.J., Ritz M.C., Goodman N.L., Sharpe L.G., Kuhar M.J., and Goldberg S.R. Differential effects of the pharmacological manipulation of serotonin systems on cocaine and amphetamine self-administration in rats. Life Sci. 45 (1989) 1529-1535
65. In: Rang H.P., Dale M.M., Ritter J.M., and Moore P.K. (Eds). Pharmacology. 5th ed. (2003), Elsevier Science, London, UK
66. Reuter M., and Hennig J. Pleiotropic effect of the TPH A779C polymorphism on nicotine dependence and personality. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134 (2005) 20-24
67. Roberts D.C., Loh E.A., Baker G.B., and Vickers G. Lesions of central serotonin systems affect responding on a progressive ratio schedule reinforced either by intravenous cocaine or by food. Pharmacol. Biochem. Behav. 49 (1994) 177-182
68. Sen S., Burmeister M., and Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127 (2004) 85-89
69. Society for Research on Nicotine and Tobacco. Biochemical verification of tobacco use and cessation. Nicotine Tob Res. 4 (2002) 149-159
70. Sprouse J.S., and Aghajanian G.K. Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1 (1987) 3-9
71. Strobel A., Gutknecht L., Rothe C., Reif A., Mossner R., Zeng Y., Brocke B., and Lesch K.P. Allelic variation in 5-HT1A receptor expression is associated with anxiety- and depression-related personality traits. J. Neural. Transm. 110 (2003) 1445-1453
72. Sullivan P.F., Jiang Y., Neale M.C., Kendler K.S., and Straub R.E. Association of the tryptophan hydroxylase gene with smoking initiation but not progression to nicotine dependence. Am. J. Med. Genet. 105 (2001) 479-484
73. Swan G.E., Valdes A.M., Ring H.Z., Khroyan T.V., Jack L.M., Ton C.C., Curry S.J., and McAfee T. Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J. 5 (2005) 21-29
74. Tucci S., Genn R.F., Marco E., and File S.E. Do different mechanisms underlie two anxiogenic effects of systemic nicotine?. Behav. Pharmacol. 14 (2003) 323-329
75. Walther D.J., Peter J.U., Bashammakh S., Hortnagl H., Voits M., Fink H., and Bader M. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299 (2003) 76
76. West R., Hajek P., Stead L., and Stapleton J. Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction 100 (2005) 299-303
77. Wu S., and Comings D.E. A common C-1018G polymorphism in the human 5-HT1A receptor gene. Psychiatr. Genet. 9 (1999) 105-106
78. Yudkin P., Hey K., Roberts S., Welch S., Murphy M., and Walton R. Abstinence from smoking eight years after participation in randomised controlled trial of nicotine patch. BMJ 327 (2003) 28-29
79. Yudkin P., Munafò M., Hey K., Roberts S., Welch S., Johnstone E., Murphy M., Griffiths S., and Walton R. Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial. BMJ 328 (2004) 989-990